Myelofibrosis epidemiology and demographics
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis epidemiology and demographics |
|
Risk calculators and risk factors for Myelofibrosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Sabawoon Mirwais, M.B.B.S, M.D.[2]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [3]
Overview
The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide. Myelofibrosis is a disease that tends to affect the middle-aged and elderly population with a mean age of 60 years at diagnosis. Males are more commonly affected than females. The male to female ratio is approximately 1.5 to 1. Myelofibrosis usually affects individuals of the Ashkenazi Jews race. African American, Latin American, and Asian individuals are less likely to develop myelofibrosis.
Epidemiology and Demographics
Incidence
- In the countries of the European Union, the incidence of myelofibrosis ranges from a low of 0.3 per 100,000 persons to a high of 1.9 per 100,000 persons with an average incidence of 1.1 per 100,000 persons.[1]
- In Olmstead County, Minnesota USA, the annual incidence of primary myelofibrosis (PMF) has been reported to be 1.33 per 100,000.[2]
Prevalence
- The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide.
- In developed countries, the prevalence of myelofibrosis is ranged from 0.5 per 100,000 per year to 9 per 100,000 per year.[1]
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
Myelofibrosis is a disease that tends to affect the middle-aged and elderly population. The mean age at diagnosis is 60 years.[3][4]
Race
- Myelofibrosis is more prevalent in the Ashkenazi Jews with an evidence of genetic transmission.[5]
Gender
- Gender distribution can differ by the subtype of the disease with primary myelofibrosis (PMF) being more prevalent in males and post-essential thrombocythemia being more common in females.[6]
- Males are more commonly affected with myelofibrosis than females with a male to female ratio of approximately 1.5 to 1.[7]
References
- ↑ 1.0 1.1 Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA (April 2014). "Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union". Eur. J. Haematol. 92 (4): 289–97. doi:10.1111/ejh.12256. PMID 24372927.
- ↑ Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
- ↑ Cloran F, Banks KP (March 2007). "AJR teaching file: Diffuse osteosclerosis with hepatosplenomegaly". AJR Am J Roentgenol. 188 (3 Suppl): S18–20. doi:10.2214/AJR.05.2141. PMID 17312082.
- ↑ Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E (November 1997). "[Idiopathic myelofibrosis: initial features, evolutive patterns and survival in a series of 106 patients]". Med Clin (Barc) (in Spanish; Castilian). 109 (17): 651–5. PMID 9488952.
- ↑ Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
- ↑ Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA (January 2017). "Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group". Haematologica. 102 (1): 85–93. doi:10.3324/haematol.2016.149559. PMC 5210236. PMID 27540137.
- ↑ Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R; et al. (2012). "One thousand patients with primary myelofibrosis: the mayo clinic experience". Mayo Clin Proc. 87 (1): 25–33. doi:10.1016/j.mayocp.2011.11.001. PMC 3538387. PMID 22212965.